DTT + JASPER for Autism
Trial Summary
What is the purpose of this trial?
This trial aims to improve language skills in preschool children with autism using a structured teaching and social interaction-based learning program. The program is adjusted based on each child's progress. The goal is to help these children develop better communication skills and avoid being minimally verbal by age 6.
Do I need to stop my current medications for the trial?
The trial requires that participants have stable medication for the past 6 months, so you should not change your current medications if you want to participate.
What data supports the effectiveness of the DTT + JASPER treatment for autism?
Research shows that JASPER, which is part of the DTT + JASPER treatment, helps improve play diversity and social interactions in children with autism. Additionally, Discrete Trial Training (DTT) has been effective in teaching language and play skills, suggesting that combining these approaches could be beneficial for children with autism.12345
Is the DTT + JASPER treatment safe for humans?
How is the DTT + JASPER treatment for autism different from other treatments?
The DTT + JASPER treatment is unique because it combines Discrete Trial Training (DTT), which is a structured teaching method, with JASPER, which focuses on improving joint attention and symbolic play skills. This combination targets specific developmental areas that are often delayed in children with autism, such as social interaction and play, which are not always the primary focus of other treatments.24689
Eligibility Criteria
The PRISM study is for preschoolers aged 36-59 months with Autism Spectrum Disorder who speak less than 20 functional words. They must have had over 3 months of early intervention, stable medication for the past half year, and a nonverbal mental age above one year. Children with sensory/motor impairments or genetic syndromes like Down Syndrome are not eligible.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Stage 1 Treatment
Participants receive either JASPER or DTT intervention for 10 weeks, 2 hours per week
Stage 2 Treatment
Early responders continue with the same intervention; slow responders are re-randomized to either intensify the current intervention or switch to Combined & Enhanced Treatment (CET)
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 10 weeks post-treatment and at age 6
Treatment Details
Interventions
- DTT (Behavioral Intervention)
- JASPER (Behavioral Intervention)
DTT is already approved in United States for the following indications:
- Autism Spectrum Disorder
- Developmental Delays